Research and development to support veriox decontamination kit to treat chemical weapon agents.
Ended Definitive Contract Awarded Last action
- Contract number
- HDTRA123C0013
- Awardee
-
Armis Biopharma, Inc. UEI WMR2HDJ79576
- Awarding agency
-
Defense Threat Reduction Agency
Department of Defense
- Obligated
- $4,759,321
Award facts
- Opportunity
-
- DTRA Chemical / Biological Technologies Broad Agency Announcement Solicitation · HDTRA120S0001 · Posted Feb 3, 2020
- Contract value 23% obligated
-
- $4,759,320.63 Current, with exercised options
- $20,289,348.85 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- 2 offers Basic Research
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Fort Collins, CO 80528, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $2,403,468 | |
| Other Administrative Action | $0 | |
| Original award | $2,355,852 |
About this award
The Defense Threat Reduction Agency awarded a definitive contract to Armis Biopharma, Inc. for research and development to support the VERIOX decontamination kit to treat chemical weapon agents on August 9, 2023, with a ceiling value of $20,289,348.85.
The contract is priced on a cost-plus-fixed-fee basis and carries an ultimate completion date of February 8, 2028. Place of performance is Fort Collins, Colorado. The originating solicitation, posted February 3, 2020, was a Broad Agency Announcement seeking proposals for chemical and biological defense technologies at Technology Readiness Levels 3 through 6, with the objective of advancing solutions to TRLs 4 through 6. The announcement evaluated proposals on scientific and technical merit, capability to perform, and overall benefit to the government, accepting continuous submissions across a one-year open period. Research addresses detection, protection, medical countermeasures, and hazard mitigation to support the Chemical and Biological Defense Program mission. Work was required to be performed within the United States for either a one or two-year period of performance.
Quick answers
Who was awarded contract HDTRA123C0013?
HDTRA123C0013 was awarded to Armis Biopharma, Inc. by Defense Threat Reduction Agency (Department of Defense) on August 9, 2023.
How much is contract HDTRA123C0013 worth?
The government has obligated $4,759,321 on HDTRA123C0013. Its potential value, with all options, is $20,289,349.
Was contract HDTRA123C0013 competed?
The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award